Search

Your search keyword '"Boehme, Angelika"' showing total 15 results
Start Over Author "Boehme, Angelika"
15 results on '"Boehme, Angelika"'

1. Treatment of Adult ALL According to Protocols of the German Multicenter Study Group for Adult ALL (GMALL)

Author

German Multicenter Study Group for Adult ALL (GMALL), Gökbuget, Nicola, Arnold, Renate, Böhme, Angelika, Fietkau, Rainer, Freund, Matthias, Ganser, Arnold, Kneba, Michael, Lipp, Thomas, Ludwig, Wolf-Dieter, Maschmeyer, Georg, Messerer, Dorle, Rieder, Harald, Thiel, Eckhard, Hoelzer, Dieter, Estey, E. H., Faderl, S. H., and Kantarjian, H. M.

Published
2008
Full Text
View/download PDF

2. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study

Author

Braulke, Friederike, Jung, Klaus, Schanz, Julie, Götze, Katharina, Müller-Thomas, Catharina, Platzbecker, Uwe, Germing, Ulrich, Brümmendorf, Tim H., Bug, Gesine, Ottmann, Oliver, Giagounidis, Aristoteles A.N., Stadler, Michael, Hofmann, Wolf-Karsten, Schafhausen, Philippe, Lübbert, Michael, Schlenk, Richard F., Blau, Igor W., Ganster, Christina, Pfeiffer, Sebastian, Shirneshan, Katayoon, Metz, Michael, Detken, Sven, Seraphin, Jörg, Jentsch-Ullrich, Kathleen, Böhme, Angelika, Schmidt, Burkhard, Trümper, Lorenz, and Haase, Detlef

Published
2013
Full Text
View/download PDF

5. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial)

Author

Cornely, Oliver A., Maertens, Johan, Bresnik, Mark, Ebrahimi, Ramin, Ullmann, Andrew J., Bouza, Emilio, Heussel, Claus Peter, Lortholary, Olivier, Rieger, Christina, Boehme, Angelika, Aoun, Mickael, Horst, Heinz-August, Thiebaut, Anne, Ruhnke, Markus, Reichert, Dietmar, Vianelli, Nicola, Krause, Stefan W., Olavarria, Eduardo, and Herbrecht, Raoul

Subjects
Amphotericin B -- Dosage and administration, Amphotericin B -- Research, Aspergillosis -- Care and treatment, Health, Health care industry
Published
2007

8. Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006–2009

Author

Schmidt, Christian, primary, Fingerle-Rowson, Guenter, additional, Boehme, Angelika, additional, Brendel, Kurt, additional, Fischer, Richard, additional, Gonnermann, Michael, additional, Höhler, Thomas, additional, Kegel, Thomas, additional, Kellermann, Lenka, additional, Nusch, Arndt, additional, Pönisch, Wolfram, additional, Wendtner, Clemens, additional, and Dreyling, Martin, additional

Published
2014
Full Text
View/download PDF

10. Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study

Author

Braulke, Friederike, primary, Schanz, Julie, additional, Metz, Michael, additional, Detken, Sven, additional, Seraphin, Joerg, additional, Götze, Katharina, additional, Mueller-Thomas, Catharina, additional, Platzbecker, Uwe, additional, Brümmendorf, Tim Henrik, additional, Giagounidis, Aristoteles A.N., additional, Germing, Ulrich, additional, Jentsch-Ullrich, Kathleen, additional, Boehme, Angelika, additional, Bug, Gesine, additional, Ottmann, Oliver G., additional, Schafhausen, Philippe, additional, Trümper, Lorenz, additional, and Haase, Detlef, additional

Published
2010
Full Text
View/download PDF

12. Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009.

Author

Schmidt, Christian, Fingerle-Rowson, Guenter, Boehme, Angelika, Brendel, Kurt, Fischer, Richard, Gonnermann, Michael, Höhler, Thomas, Kegel, Thomas, Kellermann, Lenka, Nusch, Arndt, Pönisch, Wolfram, Wendtner, Clemens, and Dreyling, Martin

Subjects
LYMPHOMA diagnosis, LYMPHOMA treatment, CHRONIC lymphocytic leukemia treatment, GRAFT versus host disease, RITUXIMAB, ERYTHROPOIETIN, IMMUNOGLOBULINS
Abstract

Today's treatment options for indolent lymphoma and chronic lymphocytic leukemia (CLL) range from watch & wait, immunochemotherapy up to allogeneic transplantation. We describe changes in the diagnosis and treatment of indolent lymphoma and CLL in Germany between 2006 and 2009. Two nation-wide surveys in the fourth quarter of 2006 and 2009 included patients with indolent lymphoma and CLL. Data from 576 patients from 46 centers in Q4/2006 were compared with data from 521 patients from 57 centers in Q4/2009. The subpopulation of patients ≥ 70 years of age and the number of patients with comorbidities increased from 39% to 55% and 47% to 55%, respectively. Both in indolent lymphoma and CLL, Rituximab and R-based immunochemotherapy (50.6% vs. 64.4%) as well as bendamustine (4.8 % vs. 24%) were much more frequently applied. In contrast, high dose chemotherapy consolidation was almost abandoned in first line treatment. Supportive care is given more frequently, with exception of erythropoietin and immunoglobulins. Our national survey confirmed that scientific results were rapidly transferred into clinical care of indolent lymphoma. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

13. Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003.

Author

Gökbuget, Nicola, Arnold, Renate, Böhme, Angelika, Fietkau, Rainer, Freund, Mathias, Ganser, Arnold, Kneba, Michael, Lipp, Thomas, Ludwig, Wolf-Dieter, Maschmeyer, Georg, Messerer, Dorle, Rieder, Harald, Thiel, Eckard, and Hoelzer, Dieter

Published
2007
Full Text
View/download PDF

15. Cytarabine Induction Followed by Imatinib Post-Induction Therapy in Patients with Acute Myeloid Leukaemia - Limited Effects in a Case Series.

Author

BRUECK, Patrick, OTTMANN, Oliver G., RAMOS-LOPEZ, Elizabeth, HOELZER, Dieter, BOEHME, Angelika, and RUMMEL, Mathias

Subjects
*CYTARABINE, *IMATINIB, *MYELOID leukemia, *COMORBIDITY, *DISEASES in older people, *CANCER chemotherapy
Abstract

Elderly patients with acute myeloid leukaemia frequently cannot undergo intensive chemotherapy due to comorbidities. We report a retrospective case series of elderly patients with AML treated with low dose cytarabine induction. Eleven patients with at least 25% of bone marrow blasts expressing c-kit received Imatinib post-induction therapy, 7 patients entered as controls. Haematologic responses were only slightly better in the Imatinib cohort. No correlation of the response to Imatinib with c-kit expression was noted. Partly due to two early deaths in the control cohort, survival was longer in the Imatinib cohort. Imatinib post-induction therapy after cytarabine induction is feasible in elderly patients with AML not eligible for standard induction but responders to Imatinib have only limited benefit from this low-toxic therapy while no predictive response markers could be found. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results